000			03107nam a22003855i 4500
001			76198
003			ES-MaUEC
005			20230207040213.0
007			cr nn 008mamaa
008			131114s2014 sz | s |||| 0|eng d
020			_a9783034807098
024	7		_a10.1007/978-3-0348-0709-8 _2doi
040			_aES-MaUEC
050		4	_aRC776.O3 _bI53 2014 EB
082	0	4	_a615
245	0	0	_aIndacaterol : _bthe first once-daily long-acting Beta2 agonist for COPD _cedited by Alexandre Trifilieff
260			_aBasel _bSpringer International Publishing _c2014
300			_a1 recurso en línea (VII, 146 p.) _b41 ilustraciones, 21 ilustraciones en color
336			_aTexto (visual) _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
490	1		_aMilestones in Drug Therapy _x2296-6056
505	0		_aCurrent Pharmacotherapy for COPD -- The preclinical pharmacology of indacaterol -- The design of the indacaterol molecule -- The early clinical development of Indacaterol -- INHANCE: An adaptive confirmatory study with dose selection at interim -- Phase III clinical efficacy studies: lung function -- Phase III Clinical Efficacy of Indacaterol -- Patient-centered Outcomes -- The history and performance of the Breezhaler device -- What does the future hold for the therapy of COPD?
520			_aChronic obstructive pulmonary disease (COPD) is a multi-component condition that results in increasingly limited airflow, usually associated with an abnormal inflammatory response of the lung. It constitutes a major public health burden worldwide, while only very few effective therapies are available. This book provides a comprehensive overview of the development of Onbrez Breezhaler, a newly approved once-daily inhaled 2 agonist for the treatment of COPD. It reviews the current pharmacotherapy for COPD and discusses topics such as the chemical design and the pre-clinical pharmacology of the molecule, the early clinical development, the INHANCE study (which provides a successful example of the use of an adaptive design in the confirmatory setting) and the Phase III clinical efficacy study, as well as the history and performance of the Breezhaler device. Finally, a list of emerging targets is included that could well offer future treatment options for COPD
942			_2lcc _cLE
988			_aEBOOK, EBSPRINGERrevisando
650		7	_aEnfermedad pulmonar obstructiva crónica _0comprobar BNE19996546854 _2embne _9155837
650		7	_aBroncodilatadores _0comprobar BNE20013344071 _2embne _9159199
700	1		_aTrifilieff, Alexandre _eeditor literario _985135 _0Local
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://link.springer.com/book/10.1007/978-3-0348-0709-8 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
901			_ai9783034807098
907			_a.b12818161 _b10-10-17 _c01-10-14
998			_am _a_alco _a_vill _b16-05-17 _cm _dz _eb _feng _gsz _h0
945			_aRC776 .O3 I53 2014 EB _g1 _ieBOOK _j0 _lmae _o- _pEUR0.00 _q- _r- _sb _t15 _u0 _v0 _w0 _x0 _y.i11547388 _z06-04-17
999			_c76198 _d76198 _x1